Organization
Shandong Suncadia Medicine
22 clinical trials
6 abstracts
Clinical trial
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Multicenter, Open Phase Ib/II Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With ER-positive, HER2-negative Unresectable or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Multi-center, Open-label Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-7085 Tablets Following Single and Multiple Oral Administrations, With Evaluation of Food Effects in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase II Clinical Study of Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in the Treatment of Patients With Chronic Kidney Disease (Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Design)Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Open-Label Assessment of the Effects of Itraconazole and Rifampicin on HRS-1780 Pharmacokinetics in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effects of Food on the Pharmacokinetics of HRS-1893 Tablets After Single and Multiple Ascending Oral Doses in Healthy Volunteers and Patients With Obstructive Hypertrophic CardiomyopathyStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Single Arm, Open, Multicenter Phase I Clinical Study on the Safety, Tolerance, and Pharmacokinetics of HRS-2189 Single Drug in Patients With Advanced Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Effect of Verapamil on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects: a Single Center, Open, Single Arm, and Fixed Sequence StudyStatus: Recruiting, Estimated PCD: 2024-05-05
Clinical trial
A Single-arm, Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-1358 Monotherapy in Patients With Metastatic or Locally Advanced Breast Cancer.Status: , Estimated PCD: 2024-06-30
Clinical trial
A Bioequivalence Study of HR20031 Tablet in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-04-04
Clinical trial
A Study to Assess the Effect of Food on HR20031 Tablet in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-03-11
Clinical trial
A Phase I Single and Multiple Ascending Dose and Food Effect Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-1780 Tablets in Healthy Male SubjectsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Multicenter, Non-randomized, Open-label, Parallel-controlled Study to Evaluate the Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal FunctionStatus: Not yet recruiting, Estimated PCD: 2023-11-30
Clinical trial
A 16-week Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on MetforminStatus: Not yet recruiting, Estimated PCD: 2023-12-21
Clinical trial
Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy SubjectsStatus: Completed, Estimated PCD: 2022-08-08
Clinical trial
A Single-dose, Open-label/Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-03-01
Abstract
A multi-center retrospective study on the efficacy and safety of regorafenib plus immune checkpoint inhibitors with or without TACE as a second-line treatment for advanced hepatocellular carcinoma.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Suncadia Medicine, China National Biotec Group,
Abstract
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China National Biotec Group, Shandong Suncadia Medicine,
Abstract
Effect of first-line bevacizumab on prognosis of second or later-line immunotherapy in patients with advanced non-squamous non-small cell lung cancer: A retrospective analysis.Org: Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan YZY Biopharma, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan,
Clinical trial
A Clinical Study to Evaluate the Relative Bioavailability of HRS-7535 Tablets of Different Formulating Processes and the Effects of Food on New Formulates (Single Center, Random, Open, Cross)Status: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Open, Multicenter Phase I Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C MutationStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Phase I Clinical Study on the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Food Effects of Single and Multiple Oral HRS-5346 Tablets in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Type 2 Diabetic Kidney DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-08-01
Abstract
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.Org: Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Jinan, Shandong Suncadia Medicine, China National Biotec Group, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China National Biotec Group, Shandong Suncadia Medicine,
Abstract
Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, Jinan,